The Daily Papule

Meeting abstracts

AAD 2026

American Academy of Dermatology · Denver, 27–31 March 2026

1,877 abstracts, published in JAAD on 6 July 2026. Their text is on the JAAD website.

  1. 70655

    Safety and Efficacy of Janus Kinase Inhibitors for Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis

    Fonseca LO, Vieira TF, … senior author Kimball A

  2. 70667

    Ruxolitinib Cream Is Efficacious in Adults With Moderate Atopic Dermatitis Regardless of Baseline Disease Severity and Previous Medication History

    Pinto PH, Asadullah K, … senior author Gooderham MJ

  3. 70710

    Efficacy and safety of deucravacitinib in genital psoriasis: data from a phase 4 study

    Bissonnette R, Barker J, … senior author Gottlieb AB

  4. 71012

    Post-Marketing Safety Profile of Topical Ruxolitinib: A FAERS Pharmacovigilance Study with Comparative Insights from Oral Upadacitinib

    Alomary S, Baker N, … senior author Taylor S

  5. 71226

    Indirect Comparisons of Janus Kinase Inhibitors and Biologic Immunotherapies for Hidradenitis Suppurativa: Results from an Updated Systematic Review and Network Meta-analysis

    Burla MM, Chater RC, … senior author Haber R

  6. 71239

    Successful management of pembrolizumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with upadacitinib

    Goetz L, Wang B

  7. 71339

    Upadacitinib in Lichen Sclerosus et Atrophicus: A Novel JAK1-Selective Approach

    Krivda K, Kakazu J, … senior author Gelman A

  8. 71498

    Efficacy of Apremilast in Patients With Mild to Moderate Psoriasis Involving the Scalp and Nails: A Post Hoc Analysis of the Phase 3 ADVANCE Study

    Gold LS, Gooderham M, … senior author Papp K

  9. 71556

    Comparative Efficacy of JAK Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison

    Babul A, Mehta D, … senior author Babul N

  10. 71564

    Efficacy of Deuruxolitinib and Ivarmacitinib, Two Recently Available Janus Kinase Inhibitors (JAKIs) for Severe Alopecia Areata (AA): A Bayesian Network Meta-Analysis (NMA) and Matching-Adjusted Indirect Comparison (MAIC)

    Babul A, Mehta D, … senior author Babul N

  11. 71668

    Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from phase 3 REMIX-1/-2 studies

    Mosnaim G, Staubach P, … senior author Giménez-Arnau AM

  12. 71835

    Efficacy and Safety of Janus Kinase Inhibitors vs Standard Therapy for Psoriatic Nail Disease: A Systematic Review and Meta-Analysis

    Martinez EC, Almeida Hidalgo JI, Floridia Rietman LM, et al.

  13. 71871

    Janus kinase inhibitors' effect on patch testing: a systematic review

    Gratz B, Chung S, Hussein A

  14. 71951

    Comparative Efficacy and Safety of Janus Kinase Inhibitors for Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis

    Shams Ul Arifeen KM, Rasheed T, … senior author Qureshy A

  15. 72182

    The impact of deucravacitinib on health-related quality of life and fatigue in patients with psoriatic arthritis: pooled analysis of phase 3 trials in patients with active psoriatic arthritis

    Gottlieb AB, Mease PJ, … senior author Strand V

  16. 72213

    Sustained Health-Related Quality of Life and work productivity improvements with Delgocitinib 20 mg/g Cream in Chronic Hand Eczema - Results from the Phase 3 Open-Label Extension DELTA 3 Trial

    Armstrong A, Gold LS, … senior author Agner T

  17. 72329

    The use of topical ruxolitinib in the treatment of localized, steroid-refractory cutaneous immune-related adverse events: A single-institution real-life study

    Block B, Mehta J, … senior author Gulati N

  18. 72508

    Navigating Access to JAK Inhibitors for Alopecia Areata: Prescribing Trends, Insurance Denials, and Treatment Delays

    Needle C, Brinks A, … senior author Lo Sicco K

  19. 72643

    Use of Apremilast for Management of Granuloma Annulare: A Systematic Review

    Kattapuram N, Batuwangala K, … senior author Hussain A

  20. 72740

    Real-World Effectiveness of Upadacitinib for Atopic Dermatitis Across Body Regions by Prior Biologic Exposure in the AD-VISE Study

    Gooderham M, Lang C, … senior author Ameen A

  21. 72751

    Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review

    Putini Vieira AC, Uliana IG, … senior author Farias de Vasconcelos RC

  22. 72815

    Examining Effectiveness of Baricitinib Therapy in Black patients with Alopecia Areata: Observations from an Open Label Study Addendum to BRAVE-AA1

    Taylor S, McMichael A, … senior author Kindred C

  23. 72824

    Delgocitinib cream 20 mg/g for moderate to severe Chronic Hand Eczema: outcomes over 16 weeks by prior systemic therapy exposure

    Bissonnette R, Schliemann S, … senior author Kircik L

  24. 72838

    2% Liposomal Tofacitinib (<200 nm) Overcomes Transcutaneous Delivery Barriers in Eyebrow Alopecia Areata: A Case Report

    Prescendo Chaves CR, Vargas P, … senior author Kreuz M

  25. 72962

    Topical PDE4 Inhibition with Crisaborole Alters Skin Microbiome Composition in Atopic Dermatitis

    Bearss J, Greene R, … senior author Mesinkovska N

  26. 72973

    Design of the REASSERT Study: A prospective, multi-country, noninterventional effectiveness and safety study evaluating remibrutinib in patients worldwide with chronic spontaneous urticaria (CSU)

    Armstrong A, Saini S, … senior author Giménez-Arnau AM

  27. 72984

    Consistency of Skin Clearance With the Targeted Oral Peptide Icotrokinra: Results From a Large Pooled Cohort of Phase 3 Study Participants With Moderate-to-Severe Plaque Psoriasis

    Gold LS, Armstrong AW, … senior author Lebwohl MG

  28. 73136

    Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry

    Olivares-Guerrero M, Jiménez-Sánchez A, … senior author Daudén E

  29. 73148

    The DELTA TEEN Phase 3 trial: systemic exposure and safety profile of delgocitinib cream in adolescents with moderate to severe Chronic Hand Eczema

    Molin S, Baselga E, … senior author Rubel D

  30. 73192

    Consistent Efficacy of Upadacitinib in Alopecia Areata Subgroups: Adult, Pediatric, Severe Disease, and JAK-Refractory Patients — A Meta-Analysis

    Barnawi G, Lazarowitz R, … senior author Donovan J

  31. 73228

    Durability of Response With Icotrokinra, a Targeted Oral Peptide, in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

    Gold LS, Armstrong AW, … senior author Bissonnette R

  32. 73233

    Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra, a Targeted Oral Peptide: Pooled Analyses of 4 Phase 3 Placebo-Controlled Trials

    Soung J, Armstrong AW, … senior author Gold LS

  33. 73330

    Stabilization of acute alopecia areata flares with short-term omalizumab in patients relapsing during JAK inhibitor treatment

    Lin J, Wang Q, … senior author Wu W

  34. 73338

    Upadacitinib for the Treatment of Refractory Alopecia Areata in Pediatric Patients: A Retrospective Study

    Wu W, Tao K, … senior author Lin J

  35. 73341

    Effect of Risankizumab Versus Deucravacitinib on Psoriasis-Related Symptoms and Quality of Life in Patients With Moderate Plaque Psoriasis: Results From the IMMpactful Trial at Week 16

    Soung J, Magnolo N, … senior author Warren RB

  36. 73422

    Assessing the Clinical Defensibility of Oral JAK Inhibitors for Short-Term Use in Moderate-to-Severe Atopic Dermatitis

    Pirrone S, Martin K

  37. 73451

    Exposure - Response (ER) Relationships of Icotrokinra in Participants With Plaque Psoriasis: Phase 3 Results

    Tammara B, Bozenhardt E, … senior author Samtani MN

  38. 73485

    Robust icotrokinra systemic and skin pharmacodynamic effects versus deucravacitinib in patients with moderate-to-severe plaque psoriasis: results from phase 3, ICONIC-ADVANCE-1 study

    Warren RB, Pieter J Van den Heuvel A, … senior author Gonzalez-Cantero A

  39. 73494

    Evaluating the Early Efficacy and Safety of Ritlecitinib in Moderate Alopecia Areata: A Real-World, Single-Center Study

    Wu W, Xu M, … senior author Lin J

  40. 73506

    Povorcitinib Demonstrates Efficacy in Patients With Chronic Spontaneous Urticaria (CSU) Regardless of Baseline Immunoglobulin E (IgE) Levels or Prior Exposure to Anti-IgE Biologics

    Metz M, Bernstein JA, … senior author Staubach P

  41. 73554

    Roflumilast Cream 0.3% and Foam 0.3% Provide Improvement Across Psoriasis Area and Severity Index Body Regions and Clinical Signs for Patients With Plaque Psoriasis

    Gooderham MJ, Bhutani T, … senior author Hanna D

  42. 73571

    The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM

    Meisenheimer J, Levine J, … senior author Hordinsky M

  43. 73591

    Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% Provides Improvements in Caregiver-Reported Outcomes That are Maintained Long Term: Results for Patients Aged 2–5 years With Mild-to-Moderate Atopic Dermatitis in the INTEGUMENT-OLE Trial

    Eichenfield L, Boguniewicz M, … senior author Simpson E

  44. 73600

    Durability of Icotrokinra (Targeted Oral Peptide) Effects in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study

    Soung J, Lebwohl MG, … senior author Eichenfield L

  45. 73603

    Early and Durable Improvements in Patient-Reported Outcomes With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study

    Soung J, Lebwohl MG, … senior author Eichenfield L

  46. 73626

    Clinical Efficacy of Small-Molecule Peptides in Anti-Aging for Sensitive Skin: A 6-Month Study

    Zhu H, Zhang C, … senior author Lu W

  47. 73642

    Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis: Subgroup Analysis of Patients With Involvement of the Face and/or Scalp in the STRATUM Trial

    Ferris LK, Cook-Bolden FE, … senior author Gooderham MJ

  48. 73744

    Real-world study in progress: Characterization and clinical outcomes of alopecia areata patients treated with ritlecitinib in a real-world cohort (PRESTO)

    Schaefer G, Kindred C, … senior author Martin C

  49. 73793

    The Role of Traditional Treatments in the Era of JAK Inhibitors: A Retrospective Cohort Study of Alopecia Areata Treatments

    Leybengrub P, Dubrovsky R, … senior author Kaufmann T

  50. 73867

    A Comparative Study of Intralesional Triamcinolone Acetonide Versus Fractional Carbon-dioxide laser assisted delivery of topical tofacitinib in alopecia areata

    Agrawal A, Khandare M